drugset / Trial / NCT06679634
Retinoblastoma Phase II Expanded Access Clinical Trial
Phase 2
Recruiting
30 enrolled
Targeted Therapy Technologies, LLC
Morgan Stanley Children's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
In this research study investigators want to learn more about treatment of advanced or recurrent retinoblastoma. For children with retinoblastoma that have an advanced stage of presentation in one eye or if they have failed all conventional treatment, eye removal is considered. This study will investigate the utility of a chemoplaque(s) to salvage eyes involved with retinoblastoma. The goal of the study is to further determine/assess the safety and efficacy and optimal chemotherapy dose for retinoblastoma.
Timeline
- Start
- 2025-02-21
- Primary completion
- 2029-11
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topotecan | Small molecule | 1.2 mg | Other |